Research programme: CSF-1R monoclonal antibodies - Eli Lilly

Drug Profile

Research programme: CSF-1R monoclonal antibodies - Eli Lilly

Alternative Names: CS7; IMC CS7; Monoclonal antibody CS7

Latest Information Update: 31 Mar 2016

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Monoclonal antibodies
  • Mechanism of Action Colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 31 Mar 2016 No recent reports on development identified - Preclinical for Solid tumours in USA (Parenteral)
  • 15 Nov 2011 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
  • 01 Jun 2011 Preclinical development for Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top